DARK SECRETS: 60 | Rare Historical Photos

2 Generic Drug Stocks Ready to Surge in 2025

Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.

MarketBeat · Nov 27, 2024

Telanagana: Spurious antibiotics worth Rs 1.33 crore seized from a pharmaceutical company

The drugs-control-administration">Drugs Control Administration, Telangana, seized a huge stock of antibiotics worth Rs 1.33 Crores from a manufacturing facility on Wednesday. Read further on Dynamite News:

Dynamite News · Nov 27, 2024

Regeneron Pharmaceuticals Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN).

Benzinga · Nov 26, 2024

Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket

Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) rose sharply in today's pre-market trading after the company agreed to be acquired by Roche in a $1.5 billion deal.

Benzinga · Nov 26, 2024

AIM ImmunoTech Issues Presentation Detailing Case For Re-Electing Current Directors To Oversee Continued Momentum And Drive Strategy To Create Long-Term Value For Patients And Shareholders; Warns Shareholders Of Its Belief That The Activist Group And Its Nominees Have A Self-Interested Agenda And Could Put AIM's Clinical Progress At Risk

Highlights How Positive Data in AIM's Clinical Pipeline and Big Pharma Partnerships are Positioning the Company for Commercialization Opportunities in High-Value Indications Including Pancreatic CancerWarns Shareholders

Benzinga · Nov 25, 2024

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analysts

Rhythm Pharmaceuticals (NASDAQ:RYTM) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

Benzinga · Nov 25, 2024

Analyst Expectations For Sarepta Therapeutics's Future

14 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:SRPT) over the past quarter, offering a diverse set of opinions from bullish to bearish.

Benzinga · Nov 25, 2024

I love the ingenious design of this women’s health brand logo

Design Bridge and Partners create a pioneering brand for the future.

Creative Bloq · Nov 24, 2024

Can BioMarin Stock Live Up to Wall Street’s High Expectations?

BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon?

MarketBeat · Nov 22, 2024

Democrats can still lower drug prices

High medication costs are a common enemy for Democrats, Republicans and patients. There's still time to fight

Salon · Nov 22, 2024